Baker Danial E
College of Pharmacy, Washington State University, Spokane, Washington, USA.
Rev Gastroenterol Disord. 2006 Summer;6(3):146-52.
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon, making it most useful in the treatment of ulcerative colitis. The MMX coating matrix and coating system begin dissolution in the final portion of the ileum. This type of oral formulation may make MMX a preferred agent over other oral mesalamine and mesalamine-prodrug formulations that release the drug proximally in the gastrointestinal tract. Unlike previous formulations, it can be administered once daily for the treatment of ulcerative colitis.
目前，大多数用于治疗溃疡性结肠炎和克罗恩病的药物递送系统会在治疗效果最差的部位释放活性药物。制药行业一直在研发用于多矩阵系统（MMX）美沙拉嗪治疗克罗恩病和溃疡性结肠炎的不同递送系统。这种新型口服美沙拉嗪制剂是一种每日服用一次的MMX片剂，可将美沙拉嗪递送至结肠，使其在溃疡性结肠炎的治疗中最为有效。MMX包衣基质和包衣系统在回肠末端开始溶解。这种口服制剂可能使MMX比其他在胃肠道近端释放药物的口服美沙拉嗪和美沙拉嗪前体药物制剂更具优势。与以前的制剂不同，它可每日服用一次用于治疗溃疡性结肠炎。
